hydroxychloroquine + sunitinib malate

Hydroxychloroquine + sunitinib malate is a combination therapy investigated by the National Cancer Institute (NCI) for the treatment of advanced solid neoplasms refractory to chemotherapy. In this regimen, hydroxychloroquine acts as an autophagy inhibitor, blocking the lysosomal degradation pathway that cancer cells often utilize to survive metabolic stress and resist cytotoxic treatments. Sunitinib malate is a multi-targeted receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR), thereby inhibiting angiogenesis and tumor cell proliferation. The combination aims to synergistically improve clinical outcomes by simultaneously disrupting tumor blood supply and the cellular recycling mechanisms that promote chemoresistance. This specific investigation was conducted as a Phase 1 dose-escalation clinical trial (NCT00813423).

Other names

HCQ + sunitinibhydroxychloroquine and sunitinib malate